a strong trendP = 0.07
Findings from a prospective, double-blind, placebo-controlled trial of 60 adults undergoing cardiac procedures involving cardiopulmonary bypass demonstrated a strong trend toward a shorter hospital LOS for patients who received IVA (1 g every 6 hours for 4 doses) than for patients who received placebo ( P = 0.07). 26 The shorter LOS was attributed to reductions in overall opioid consumption and therefore opioid-related adverse events when IVA was used in an MMA regimen.